IIT Research Institute has been awarded a contract for up to $9 million for preclinical services to support the National Cancer Institute (NCI) Preclinical PREVENT Cancer Program – Toxicology and Pharmacology Testing. This NCI program was initiated to bring new high-priority cancer PREVENTing therapeutics and biomarkers through preclinical development towards clinical evaluations.

Building on the many years of NCI collaborations, IITRI will continue to support In vitro and in vivo preclinical pharmacology, efficacy and toxicology studies for potential new cancer drugs through contract collaborations.

Contact us to learn more about how our nonclinical capabilities can support your drug discovery and development program.